Literature DB >> 9888855

Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.

D A Fruman1, S B Snapper, C M Yballe, L Davidson, J Y Yu, F W Alt, L C Cantley.   

Abstract

Phosphoinositide 3-kinase (PI3K) activation has been implicated in many cellular responses, including fibroblast growth, transformation, survival, and chemotaxis. Although PI3K is activated by several agents that stimulate T and B cells, the role of PI3K in lymphocyte function is not clear. The mouse gene encoding the PI3K adapter subunit p85alpha and its splice variants p55alpha and p50alpha was disrupted. Most p85alpha-p55alpha-p50alpha-/- mice die within days after birth. Lymphocyte development and function was studied with the use of the RAG2-deficient blastocyst complementation system. Chimeric mice had reduced numbers of peripheral mature B cells and decreased serum immunoglobulin. The B cells that developed had diminished proliferative responses to antibody to immunoglobulin M, antibody to CD40, and lipopolysaccharide stimulation and decreased survival after incubation with interleukin-4. In contrast, T cell development and proliferation was normal. This phenotype is similar to defects observed in mice lacking the tyrosine kinase Btk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888855     DOI: 10.1126/science.283.5400.393

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  179 in total

1.  Alternative modes of binding of proteins with tandem SH2 domains.

Authors:  R O'Brien; P Rugman; D Renzoni; M Layton; R Handa; K Hilyard; M D Waterfield; P C Driscoll; J E Ladbury
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

Review 2.  Immunoglobulin class switch recombination: will genetics provide new clues to mechanism?

Authors:  N Maizels
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

3.  Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase.

Authors:  Lei Bi; Ichiro Okabe; David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

Review 4.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

5.  Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.

Authors:  Hajir Dadgostar; Brian Zarnegar; Alexander Hoffmann; Xiao-Feng Qin; Uyen Truong; Govinda Rao; David Baltimore; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

6.  A differential requirement for phosphoinositide 3-kinase reveals two pathways for inducible upregulation of major histocompatibility complex class II molecules and CD86 expression by murine B lymphocytes.

Authors:  Stuart Marshall-Clarke; Lynn Tasker; Mark P Heaton; R Michael E Parkhouse
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

7.  X-chromosome-linked immune-deficient mice have B-1b cells.

Authors:  J Riggs; K Howell; B Matechin; R Matlack; A Pennello; R Chiasson
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

8.  The conserved phosphoinositide 3-kinase pathway determines heart size in mice.

Authors:  T Shioi; P M Kang; P S Douglas; J Hampe; C M Yballe; J Lawitts; L C Cantley; S Izumo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

9.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.

Authors:  T Simoncini; A Hafezi-Moghadam; D P Brazil; K Ley; W W Chin; J K Liao
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

10.  Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.

Authors:  Marie H Solheim; Jonathon N Winnay; Thiago M Batista; Anders Molven; Pål R Njølstad; C Ronald Kahn
Journal:  Diabetes       Date:  2018-05-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.